The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2758-2770

  Stone, Virginia M ^a   Dhayal, Shalinee ^a   Smith, David M ^b   Lenaghan, Carol ^b   Brocklehurst, Katy J ^b   Morgan, Noel G ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Anadamide; Arachidonate; Fatty acid amide hydrolase; Lipotoxicity; Oleate; Palmitate

Indexed keywords

ANANDAMIDE; ARACHIDONIC ACID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; INSULIN; N OLEOYLETHANOLAMINE; OLEIC ACID; PROTEIN GPR119; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CLONING; CELL PROTECTION; CELL SELECTION; CELL STRAIN; CELL STRAIN BRIN BD11; CELL STRAIN INS 1E; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE; CELL SURVIVAL; CYCLIC AMP; CYTOPROTECTION; FATTY ACIDS; INSULIN; INSULIN-SECRETING CELLS; OLEIC ACIDS; RATS; RECEPTORS, G-PROTEIN-COUPLED; SERUM ALBUMIN, BOVINE;

EID: 84859094843     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01755.x     Document Type: Article

References (51)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB (1992). Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130: 167-178.
3. Astarita G, Di Giacomo B, Gaetani S, Oveisi F, Compton TR, Rivara S et al. (2006). Pharmacological characterization of hydrolysis-resistant Analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther 318: 563-570. (Pubitemid 44061230)
4. Borrelli F, Izzo AA (2009). Role of acylethanolamides in the gastrolintestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 23: 33-49.
5. Chu Z-L, Jones RM, He H, Carroll C, Gutierrez V, Lucman A et al. (2007). A role for beta-cell expressed G Protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148: 2601-2609. (Pubitemid 46984798)
6. Chu Z-L, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A et al. (2008). A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149: 2038-2047. (Pubitemid 351574507)
7. Cluny NL, Keenan CM, Lutz R, Piomelli D, Sharkey KA (2009). The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil 21: 420-429.
8. Dhayal S, Morgan NG (2010). The significance of GPR119 agonists as a future treatment for type 2 diabetes. Drug News Perspect 23: 418-424.
9. Dhayal S, Morgan NG (2011). Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells. Br J Pharmacol 162: 1340-1350.
10. Dhayal S, Welters HJ, Morgan NG (2008). Structural requirements for the cytoprotective actions of mono-unsaturated fatty acids in the pancreatic beta-cell line, BRIN-BD11. Br J Pharmacol 153: 1718-1727. (Pubitemid 351536000)
11. Diakogiannaki E, Dhayal S, Childs CE, Calder PC, Welters HJ, Morgan NG (2007). Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long-chain fatty acids in pancreatic beta-cells. J Endocrinol 194: 283-291. (Pubitemid 47249667)
12. Diakogiannaki E, Welters HJ, Morgan NG (2008). Differential regulation of the endoplasmic reticulum stress response in pancreatic beta-cells exposed to long-chain saturated and monounsaturated fatty acids. J Endocrinol 197: 553-563. (Pubitemid 351803959)
13. Di Marzo V, Bisogno T, Melcka D, Rossb R, Brockieb H, Stevensonb L et al. (1998). Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett 436: 449-454. (Pubitemid 28482980)
14. Eder K, Ringseis R (2010). The role of peroxisome proliferator-activated receptor alpha in transcriptional regulation of novel organic cation transporters. Eur J Pharmacol 628: 1-5.
15. Eitel K, Staiger H, Brendel MD, Brandhorst D, Bretzel RG, Haring HU et al. (2002). Different role of saturated and unsaturated fatty acids in beta-cell apoptosis. Biochem Biophys Res Commun 299: 853-856. (Pubitemid 36034564)
16. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G et al. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352-358. (Pubitemid 40411361)
17. Fowler CJ, Jacobsson SO (2002). Cellular transport of anandamide, 2-arachidonylglycerol and palmitoylethanolamide - targets for drug development? Prostaglandins, Leukot Essent Fatty Acids 66: 193-200. (Pubitemid 34743594)
18. Gehrmann W, Elsner M, Lenzen S (2010). Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic beta-cells. Diabetes Obes Metab 12: 149-158.
19. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG (2003). Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100: 4269-4274. (Pubitemid 36418192)
20. Hillard CJ, Jarrahian A (2000). The movement of N- arachidonoylethanolamide (anandamide) across cellular membranes. Chem Phys Lipids 108: 123-134.
21. Hillard CJ, Jarrahian A (2003). Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 140: 802-808. (Pubitemid 37464061)
22. Ho W-S, Barrett DA, Randall MD (2008). 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155: 837-846.
23. Hogestatt ED, Jonsson BAG, Ermund A, Andersson DA, Bjork H, Alexander JP et al. (2005). Conversion of Acetaminophen to the Bioactive N-Acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280: 31405-31412. (Pubitemid 41291881)
24. Izzo AA, Piscitelli F, Capasso R, Marini P, Cristino L, Petrosino S et al. (2009). Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker rats. Obesity (Silver Spring) 18: 55-62.
25. Karbarz MJ, Luo L, Chang L, Tham C-S, Palmer JA, Wilson SJ et al. (2009). Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth Analg 108: 316-329.
26. Keith JM, Apodaca R, Xiao W, Seierstad M, Pattabiraman K, Wu J et al. (2008). Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 18: 4838-4843.
27. Labar G, Michaux C (2007). Fatty acid amide hydrolase: from charaterization to therapeutics. Chem Biodivers 4: 1882-1902. (Pubitemid 47377207)
28. Lan H, Vassileva G, Corona A, Liu L, Golovko A, Abbondanzo SJ et al. (2009). GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 201: 219-230.
29. Lauffer LM, Iakoubov R, Brubaker PL (2009). GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58: 1058-1066.
30. Madiraju SR, Poitout V (2007). G protein-coupled receptors and insulin secretion: 119 and counting. Endocrinology 148: 2598-2600. (Pubitemid 46984778)
31. Martinez de Ubago M, Garcia-Oya I, Perez-Perez A, Canfran-Duque A, Quintana-Portillo R, Rodriguez de Fonseca F et al. (2009). Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells. Biochim Biophys Acta 1791: 740-745.
32. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW et al. (1996). Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45: 1132-1140. (Pubitemid 26260168)
33. Morgan NG, Dhayal S, Diakogiannaki E, Welters HJ (2008). The cytoprotective actions of long-chain mono-unsaturated fatty acids in pancreatic beta-cells. Biochem Soc Trans 36: 905-908.
34. Murillo-Rodriguez E, Vazquez E, Millan-Aldaco D, Palomero-Rivero M, Drucker-Colin R (2007). Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur J Pharmacol 562: 82-91. (Pubitemid 46466764)
35. Newsholme P, Keane D, Welters HJ, Morgan NG (2007). Life and death decisions of the pancreatic beta-cell: the role of fatty acids. Clin Sci 112: 27-42. (Pubitemid 46120083)
36. Ning Y, O'Neill K, Lan H, Pang L, Shan L, Hawes BE et al. (2008). Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol 155: 1056-1065.
37. Overton HA, Babbs AJ, Doel SM, Fyfe MCT, Gardner LS, Griffin G et al. (2006). Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3: 167-175.
38. Overton HA, Fyfe MCT, Reynet C (2008). GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 153: S76-S81. (Pubitemid 351340991)
39. Patel S, Carrier EJ, Ho W-S, Rademacher DJ, Cunningham S, Reddy DS et al. (2005). The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 46: 342-349. (Pubitemid 40271098)
40. Ralevia V, Kendalla DA, Jermanb JC, Middlemissb DN, Darren S (2001). Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol 424: 211-219.
41. Ropero AB, Juan-Pico P, Rafacho A, Fuentes E, Bermudez-Silva FJ, Roche E et al. (2009). Rapid non-genomic regulation of Ca2+ signals and insulin secretion by PPAR alpha ligands in mouse pancreatic islets of Langerhans. J Endocrinol 200: 127-138.
42. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson N-O, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101. (Pubitemid 350166046)
43. Shah U, Kowalski TJ (2010). GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Vitamins and Hormones: Incretins and Insulin Secretion. Elsevier Academic Press Inc: San Diego.
44. Swaminath G (2008). Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch Pharm 341: 753-761.
45. Szewczyk JW, Acton J, Adams AD, Chicchi G, Freeman S, Howard AD et al. (2011). Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Medicinal Chem Lett 21: 2665-2669.
46. Talukdar S, Olefsky JM, Osborn O (2011). Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32: 543-550.
47. Tang X, Edwards EM, Holmes BB, Falck JR, Campbell WB (2006). Role of phospholipase C and diacylglyceride lipase pathway in arachidonic acid release and acetylcholine-induced vascular relaxation in rabbit aorta. Am J Physiol Heart Circ Physiol 290: H37-H45.
48. Thorn K, Bergsten P (2010). Fatty acid-induced oxidation and triglyceride formation is higher in insulin-producing MIN6 cells exposed to oleate compared to palmitate. J Cell Biochem 111: 497-507.
49. Welters HJ, Tadayyon M, Scarpello JHB, Smith SA, Morgan NG (2004). Mono-unsaturated fatty acids protect against beta-cell apoptosis induced by saturated fatty acids, serum withdrawal or cytokine exposure. FEBS Lett 560: 103-108. (Pubitemid 38264301)
50. Xia Y, Chackalamannil S, Greenlee WJ, Jayne C, Neustadt B, Hawes B et al. (2011). Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type II diabetes. Bioorg Medicinal Chem Lett 21: 3290-3296.
51. Yoshida S, Ohishi T, Matsui T, Tanaka H, Oshima H, Yonetoku Y et al. (2010). Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem Biophys Res Commun 402: 280-285.